Gert O. De Meerleer

Prof. Gert O. De Meerleer


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
GMGert O. De Meerleer
Gert O. De Meerleer
CBCharlien Berghen
Charlien Berghen
ABAlberto Briganti
Alberto Briganti
CVChristof Vulsteke
Christof Vulsteke
JMJulia Murray
Julia Murray
ABAlberto Bossi
Alberto Bossi

21 November 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
HEHans Van der Eecken
Hans Van der Eecken
Steven JoniauSteven Joniau
Steven Joniau
CBCharlien Berghen
Charlien Berghen
KRKato Rans
Kato Rans
GMGert O. De Meerleer
Gert O. De Meerleer
A possible link between diet and cancer has long been considered, with growing interest in phytochemicals. Soy isoflavones have been associated with a reduced risk of prostate cancer in Asian populations. Of the soy isoflavones, genistein and daidzein, in particular, have been studied, but recently, equol as a derivative has gained interest because it is more biologically potent. Different mechanisms of action have already been studied for the different isoflavones in multiple conditions, such as breast, gastrointestinal, and urogenital cancers. Many of these mechanisms of action could also be demonstrated in the prostate, both in vitro and in vivo. This review focuses on the known mechanisms of action at the cellular level and compares them between genistein, daidzein, and equol. These include androgen- and estrogen-mediated pathways, regulation of the cell cycle and cell proliferation, apoptosis, angiogenesis, and metastasis. In addition, antioxidant and anti-inflammatory effects and epigenetics are addressed.


8 April 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
NFNicola Rares Franco
Nicola Rares Franco
MMMichela Carlotta Massi
Michela Carlotta Massi
FIFrancesca Ieva
Francesca Ieva
AMAndrea Manzoni
Andrea Manzoni
APAnna Maria Paganoni
Anna Maria Paganoni
SGSheryl Green
Sheryl Green
To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 literature-identified SNPs, the 30% most strongly associated with each toxicity were tested. SNP-SNP combinations (named SNP-allele sets) seen in ≥10% of the cohort were condensed into risk (RS) and protection (PS) scores, respectively indicating increased or decreased toxicity risk. Performance of RS and PS was evaluated by logistic regression. RS and PS were then combined into a single PRSi evaluated by area under the receiver operating characteristic curve (AUC). Among 1,387 analysed patients, toxicity rates were 11.7% (rectal bleeding), 4.0% (urinary frequency), 5.5% (haematuria), 7.8% (nocturia) and 17.1% (decreased urinary stream). RS and PS combined 8 to 15 different SNP-allele sets, depending on the toxicity endpoint. Distributions of PRSi differed significantly in patients with/without toxicity with AUCs ranging from 0.61 to 0.78. PRSi was better than the classical summed PRS, particularly for the urinary frequency, haematuria and decreased urinary stream endpoints. Our method incorporates SNP-SNP interactions when calculating PRS for radiotherapy toxicity. Our approach is better than classical summation in discriminating patients with toxicity and should enable incorporating genetic information to improve normal tissue complication probability models.

22 September 2017 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KWKatrien De Wolf
Katrien De Wolf
SRSylvie Rottey
Sylvie Rottey
KVKarim Vermaelen
Karim Vermaelen
KDKarel Decaestecker
Karel Decaestecker
NSNora Sundahl
Nora Sundahl
POPiet Ost
Piet Ost
The primary objective was to determine maximum tolerated radiation dose in patients with metastatic renal cell carcinoma on pazopanib treatment. Treatment-naïve patients received pazopanib according to standard of care. Stereotactic body radiotherapy (SBRT) was delivered concurrently to the largest metastatic lesion at day 8, 10 and 12. SBRT doses were escalated in 3 dose levels (24 Gy/3, 30 Gy/3 and 36 Gy/3). Dose level was assigned using Time-to-Event Continual Reassessment Method with the target dose-limiting toxicity rate set to 0.25. Thirteen patients were included. One patient experienced dose limiting toxicity (DLT) at dose level 3 (grade 4 hypoglycemia). Maximum tolerated dose was not reached with a recommended dose of 36 Gy/3 having a probability of DLT of 11%. One-year local control was 83% (95% confidence interval 61–100) and 1-year progression-free survival was 28% (95% confidence interval 1–55). SBRT in combination with pazopanib is well tolerated with good local control and response rates outside the radiation field. This trial was retrospectively registered on clinicaltrials.gov( NCT02334709 ) on January 6th, 2015.

20 February 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
NSNina-Sophie Schmidt-Hegemann
Nina-Sophie Schmidt-Hegemann
Constantinos ZamboglouConstantinos Zamboglou
Constantinos Zamboglou
MMMalcolm Mason
Malcolm Mason
NMNicolas Mottet
Nicolas Mottet
KHKarel Hinnen
Karel Hinnen
TWThomas Wiegel
Thomas Wiegel